TY - JOUR AU - Siasos, Gerasimos AU - Tsigkou, Vasiliki AU - Kosmopoulos, Marinos AU - Theodosiadis, Dimosthenis AU - Simantiris, Spyridon AU - Tagkou, Nikoletta Maria AU - Tsimpiktsioglou, Athina AU - Stampouloglou, Panagiota K. AU - Oikonomou, Evangelos AU - Mourouzis, Konstantinos AU - Philippou, Anastasios AU - Vavuranakis, Manolis AU - Stefanadis, Christodoulos AU - Tousoulis, Dimitris AU - Papavassiliou, Athanasios G. PY - 2018 TI - Mitochondria and cardiovascular diseases—from pathophysiology to treatment JF - Annals of Translational Medicine; Vol 6, No 12 (June 30, 2018): Annals of Translational Medicine (Focus on “Molecular Medicine”) Y2 - 2018 KW - N2 - Mitochondria are the source of cellular energy production and are present in different types of cells. However, their function is especially important for the heart due to the high demands in energy which is achieved through oxidative phosphorylation. Mitochondria form large networks which regulate metabolism and the optimal function is achieved through the balance between mitochondrial fusion and mitochondrial fission. Moreover, mitochondrial function is upon quality control via the process of mitophagy which removes the damaged organelles. Mitochondrial dysfunction is associated with the development of numerous cardiac diseases such as atherosclerosis, ischemia-reperfusion (I/R) injury, hypertension, diabetes, cardiac hypertrophy and heart failure (HF), due to the uncontrolled production of reactive oxygen species (ROS). Therefore, early control of mitochondrial dysfunction is a crucial step in the therapy of cardiac diseases. A number of anti-oxidant molecules and medications have been used but the results are inconsistent among the studies. Eventually, the aim of future research is to design molecules which selectively target mitochondrial dysfunction and restore the capacity of cellular anti-oxidant enzymes. UR - https://atm.amegroups.org/article/view/20070